BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33127625)

  • 1. Feasibility of Single-Time-Point Dosimetry for Radiopharmaceutical Therapies.
    Hou X; Brosch J; Uribe C; Desy A; Böning G; Beauregard JM; Celler A; Rahmim A
    J Nucl Med; 2021 Jul; 62(7):1006-1011. PubMed ID: 33127625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward Single-Time-Point Image-Based Dosimetry of
    Brosch-Lenz J; Delker A; Völter F; Unterrainer LM; Kaiser L; Bartenstein P; Ziegler S; Rahmim A; Uribe C; Böning G
    J Nucl Med; 2023 May; 64(5):767-774. PubMed ID: 36657980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy and uncertainty analysis of reduced time point imaging effect on time-integrated activity for
    Peterson AB; Mirando DM; Dewaraja YK
    EJNMMI Res; 2023 Jun; 13(1):57. PubMed ID: 37306783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy and uncertainty analysis of reduced time point imaging effect on time-integrated activity for 177Lu-DOTATATE PRRT in clinical patients and realistic simulations.
    Peterson AB; Mirando DM; Dewaraja YK
    Res Sq; 2023 Apr; ():. PubMed ID: 37131738
    [No Abstract]   [Full Text] [Related]  

  • 5. Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and Population-Based Model Selection in [
    Hardiansyah D; Yousefzadeh-Nowshahr E; Kind F; Beer AJ; Ruf J; Glatting G; Mix M
    J Nucl Med; 2024 Apr; 65(4):566-572. PubMed ID: 38423787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of voxel S-value methods for personalized voxel-based dosimetry of
    Kim KM; Lee MS; Suh MS; Selvam HSMS; Tan TH; Cheon GJ; Kang KW; Lee JS
    Med Phys; 2022 Mar; 49(3):1888-1901. PubMed ID: 35014699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-Time-Point Imaging for Dosimetry After [
    Wang C; Peterson AB; Wong KK; Roseland ME; Schipper MJ; Dewaraja YK
    J Nucl Med; 2023 Sep; 64(9):1463-1470. PubMed ID: 37500260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy and reproducibility of simplified QSPECT dosimetry for personalized
    Del Prete M; Arsenault F; Saighi N; Zhao W; Buteau FA; Celler A; Beauregard JM
    EJNMMI Phys; 2018 Oct; 5(1):25. PubMed ID: 30318563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy of kidney dosimetry performed using simplified time activity curve modelling methods: a
    Zhao W; Esquinas PL; Frezza A; Hou X; Beauregard JM; Celler A
    Phys Med Biol; 2019 Aug; 64(17):175006. PubMed ID: 31287093
    [No Abstract]   [Full Text] [Related]  

  • 10. Personalized kidney dosimetry in
    Hou X; Zhao W; Beauregard JM; Celler A
    Phys Med Biol; 2019 Aug; 64(17):175004. PubMed ID: 31456584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
    Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Streamlined Schemes for Dosimetry of
    Kurth J; Heuschkel M; Tonn A; Schildt A; Hakenberg OW; Krause BJ; Schwarzenböck SM
    Cancers (Basel); 2021 Aug; 13(15):. PubMed ID: 34359784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lu-177-PSMA dosimetry for kidneys and tumors based on SPECT images at two imaging time points.
    Chen G; Lu Z; Jiang H; Afshar-Oromieh A; Rominger A; Shi K; Mok GSP
    Front Med (Lausanne); 2023; 10():1246881. PubMed ID: 38020081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examining Absorbed Doses of Indigenously Developed
    Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
    Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
    [No Abstract]   [Full Text] [Related]  

  • 16. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
    Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
    J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [
    Kurth J; Krause BJ; Schwarzenböck SM; Bergner C; Hakenberg OW; Heuschkel M
    Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):123-135. PubMed ID: 31482426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
    Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in
    Rinscheid A; Kletting P; Eiber M; Beer AJ; Glatting G
    Med Phys; 2019 Dec; 46(12):5861-5866. PubMed ID: 31587333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simplified patient-specific renal dosimetry in
    Ligonnet T; Pistone D; Auditore L; Italiano A; Amato E; Campennì A; Schaefer N; Boughdad S; Baldari S; Gnesin S
    Phys Med; 2021 Dec; 92():75-85. PubMed ID: 34875425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.